Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.32 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.32 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22069030 | 0.82 | PDE10A (0.35) | MAPTMTORC5AR1DDB1CRBN | |
| SCHEMBL28700403 | 0.82 | L3MBTL1 (0.41) | MAPTL3MBTL1MTORHDAC1HDAC6 | |
| SCHEMBL22069334 | 0.80 | L3MBTL1 (0.34) | MAPTL3MBTL1MTORHDAC1HDAC6 | |
| SCHEMBL22068975 | 0.77 | MAPT (0.37) | MAPTL3MBTL1MTORHDAC1HDAC6 | |
| SCHEMBL22068991 | 0.75 | GCK (0.37) | MAPTL3MBTL1MTORHDAC1HDAC6 | |
| SCHEMBL22715571 | 0.75 | ADORA1 (0.46) | MAPTMTORC5AR1DDB1CRBN | |
| SCHEMBL22738284 | 0.73 | MAPT (0.41) | MAPTMTORC5AR1DDB1CRBN | |
| SCHEMBL22029691 | 0.72 | ADORA1 (0.51) | MAPTMTORC5AR1DDB1CRBN | |
| SCHEMBL22727594 | 0.72 | MAPT (0.40) | MAPTMTORHDAC1HDAC6C5AR1 | |
| SCHEMBL22102760 | 0.71 | PARP1 (0.40) | MAPTMTORC5AR1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2021-08-19 | — | — | US | disclosed |
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | NOVIRA THERAPEUTICS, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3478692-B1 | OXADIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS | NOVIRA THERAPEUTICS INC (US) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10987359-B2 | Oxadiazepinone derivatives and methods of treating hepatitis B infections | HCCS, SLC10A1, PYGL | MAPT 4786/4885L3MBTL1 4809/4885MTOR 2080/4885 |
| US-20210252014-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HAVCR2, PYGL, HCCS | MAPT 4805/4885L3MBTL1 4655/4885MTOR 2291/4885 |
| US-20200197408-A1 | OXADIAZEPINONE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | HCCS, SLC10A1, PYGL | MAPT 4786/4885L3MBTL1 4809/4885MTOR 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.